Expert Outlook: Intellia Therapeutics Through The Eyes Of 7 Analysts
Portfolio Pulse from Benzinga Insights
Intellia Therapeutics (NASDAQ:NTLA) has received mixed analyst ratings over the past three months, with a majority being somewhat bullish. Analysts have adjusted their price targets, with an average target of $70.86, down from $74.86. The company faces financial challenges, including a significant revenue decline and negative profitability metrics.
September 11, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Intellia Therapeutics has received mixed analyst ratings, with a majority being somewhat bullish. The average price target has decreased slightly, reflecting cautious optimism. The company faces financial challenges, including a significant revenue decline and negative profitability metrics.
The mixed analyst ratings indicate a cautious market sentiment towards Intellia Therapeutics. The slight decrease in the average price target suggests tempered expectations. Financial challenges, such as declining revenue and negative profitability, may weigh on the stock's short-term performance, balancing the somewhat bullish analyst outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100